Diabetes Presentation Pt 1 Final
-
Upload
jenifer-denormandie -
Category
Documents
-
view
14 -
download
0
Transcript of Diabetes Presentation Pt 1 Final
![Page 1: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/1.jpg)
Managing Diabetes Mellitus
By Karina Bonitto and Jenifer DeNormandie
![Page 2: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/2.jpg)
Learning Objectives
⦿Review the pathophysiology of Diabetes and how it relates to therapy⦿Summarize available treatment options
for diabetes mellitus ⦿Describe different methods of glucose
logging to meet the needs of patients⦿Recall techniques to help patients be
more comfortable with injectable therapy
![Page 3: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/3.jpg)
Road Map
⦿Today●Epidemiology●Pathophysiology●Types of diabetes●Treatment options
○ Oral agents○ Injectable therapy○ Side effects
●Guidelines●Carb counting●Home monitoring●Smart phone Apps●Cases
⦿Next week● Complications● Microvascular
○ Eye Disease○ Neuropathy○ Nephropathy
● Macrovascular○ CHD○ PAD○ CVD
● Other
![Page 4: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/4.jpg)
Epidemiology: The Diabetes Epidemic: Global Projections 2010–2030
IDF. Diabetes Atlas 5th Ed. 2011
![Page 5: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/5.jpg)
Pathophysiology⦿Diabetes is a group of metabolic disorders that
results in hyperglycemia and metabolism abnormalities
![Page 6: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/6.jpg)
Classification
⦿Type 1⦿Type 2⦿Gestational⦿Drug induced
![Page 7: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/7.jpg)
Type 1 (Insulin dependent)⦿Usually in young adults and adolescents
●Can present at any age●Ketoacidosis is more common
⦿Total insulin deficiency which is often due to beta cell destruction.●immune mediated
○ macrophages and T lymphocytes with autoantibodies to beta cell antigens⦿Typical presentation: polyuria, polydipsia,
nausea, blurred vision due to hyperglycemia
![Page 8: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/8.jpg)
Diabetic Ketoacidosis⦿Caused by increased fatty acid metabolism
and accumulation of ketoacids ⦿ Triggered by infections and problems with insulin therapy⦿Can be fatal⦿Symptoms can develop quickly● Polydipsia, SOB, confusion, fatigue, n/v,
frequent urination, fruity scented breath⦿ Labs: hyperglycemia, anion gap acidosis, ketonuria or ketonemia⦿ Treatment: IV regular insulin, fluid resuscitation
![Page 9: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/9.jpg)
Type 2 (Non-insulin dependent) ⦿Majority of diabetes cases (90-95%)⦿Insulin resistance and progressively lowering
insulin secretion● Insulin resistance often manifests as increased
lipolysis and free fatty acid production, increased hepatic glucose production, and decreased glucose uptake by skeletal muscle⦿Abdominal obesity
⦿Co-morbidities often present⦿Typical presentation: retinopathy, neuropathy,
nephropathy, obesity, HTN
![Page 10: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/10.jpg)
Type 1 Vs Type 2Type 1 Type 2
Etiology Autoimmune Insulin resistance
Age of Onset Younger Older
Family History Rare Common
Obesity Rare Common
Insulin Resistance No Yes
Ketosis Yes No
Genetic association (HLA)
Yes No
Insulin presence within the body
No Yes
Response to oral agents
No Yes
![Page 11: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/11.jpg)
Gestational Diabetes Mellitus
⦿Hormonal changes result in insulin resistance⦿New onset glucose intolerance during
pregnancy⦿Usually presents in third trimester
![Page 12: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/12.jpg)
Drug Induced Diabetes⦿Pentamidine⦿Glucocorticoids⦿Atypical antipsychotics⦿Protease inhibitors⦿Hydrochlorothiazide⦿Diazoxide⦿Interferon (alpha)⦿Nicotinic acid
![Page 13: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/13.jpg)
Diagnosis
⦿Any of the following:●A1C ≥ 6.5%●Fasting plasma glucose (FPG) ≥126 mg/dL●2 hour OGTT ≥ 200 mg/dL●Random plasma glucose ≥ 200 mg/dL
![Page 14: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/14.jpg)
Pharmacologic Treatment⦿Metformin⦿Insulin
secretagogues⦿Thiazolidinediones⦿Alpha-GI⦿DPP-4 inhibitors⦿GLP-1 RA⦿Amylin analogs⦿Bile Acid
sequestrants
⦿DA agonists⦿SGLT-2 inhibitors⦿Insulins
●Rapid●Short●Intermediate●Long
![Page 15: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/15.jpg)
Goals of Treatment
⦿Reduce the risk of microvascular and macrovascular complications⦿Ameliorate symptoms⦿Reduce mortality⦿Improve QOL
![Page 16: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/16.jpg)
Treatment Options: Metformin⦿Gold standard⦿Enhances insulin sensitivity of hepatic and
peripheral tissues⦿BBW: Lactic acidosis⦿Contraindicated if SCr ≥1.5 or ≥1.4 (f)⦿Dosing
●IR: 500mg BID with food●ER: 500mg 1 QD with evening meal●Max: 2500mg daily
![Page 17: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/17.jpg)
Treatment Options: Insulin Secretagogues⦿Stimulate insulin secretion from beta-cells⦿Maximal glycemic control at 6 months⦿Contraindicated in T1DM, DKA, concurrent used
with bosentan (glyburide) or gemfibrozil (repaglinide)⦿Dosing
●Glyburide 2.5-5 mg/day●Glipizide 5 mg/day●Glimepiride 1-2 mg/day●Nateglinide 120 mg TID●Repaglinide 0.5-2 mg before each meal dependent on
HbA1C
![Page 18: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/18.jpg)
Treatment Options: Thiazolidinediones (TZDs)⦿Similar efficacy with glycemic control⦿Pioglitazone reduces mortality, MI, and stroke
in high risk patients⦿BBW: CHF⦿Contraindicated in CHF and pulmonary
edema⦿Dosing
●Pioglitazone 15 or 30 mg QD●Rosiglitazone 4 mg/day
![Page 19: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/19.jpg)
Treatment Options: Alpha-GI⦿Delays and reduces post-meal carbohydrate
absorption and postprandial blood glucose⦿Contraindicated in IBD, intestinal obstruction,
malabsorption, cirrhosis, and CrCl< 25mL/min or SCr>2mg/dL⦿Dosing
●Arcarbose (Precose): 25mg with the first bite of meal once a day then increase weekly to 2 times/day then 3 times/day
●Miglitol (Glyset): 25 mg with the first bite of meal
![Page 20: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/20.jpg)
Treatment Options: DPP-4 Inhibitors⦿Increases insulin secretion from beta-cells
and decreases glucagon secretion from alpha-cells⦿Caution: Acute pancreatitis, joint pain,
hepatotoxicity (alogliptin)⦿Dosing
●Sitagliptin 100 mg QD●Saxagliptin 2.5-5 mg QD●Linagliptin 5 mg QD●Alogliptin 25 mg QD
![Page 21: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/21.jpg)
Treatment Options: GLP-1 RA⦿ Increases insulin secretion, decreases
glucagon secretion and slows gastric emptying
⦿BBW: Thyroid C-cell tumor risk (excludes exenatide IR)
⦿Dosing● Exenatide IR: 5 mcg SC BID x 1 month then
10 mcg SC BID (1 hour before meals)● Exenatide ER: 2 mg SC Weekly● Liraglutide: 0.6 mg SC QD x 1 week , then 1.2
mg SC QD● Dulaglutide: 0.75 mg SC Weekly● Abiglutide: 30 mg SC Weekly
![Page 22: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/22.jpg)
Treatment Options: Amylin Analogs⦿Slows gastric emptying and suppresses
postprandial glucose⦿BBW: Co-administration with insulin increases
the risk of hypoglycemia⦿Contraindications: gastroparesis,
hypoglycemic unawareness⦿Reduce mealtime insulin by 50%⦿Dosing
●Type 1: Pramlintide 15 mcg before meals●Type 2: Pramlintide 60 mcg before meals
![Page 23: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/23.jpg)
Treatment Options: Bile Acid Sequestrants⦿Binds bile acids and decreases hepatic
glucose production⦿Contraindicated with bowel obstruction,
triglycerides > 500 mg/dL, or history of hypertriglyceridemia-induced pancreatitis⦿Dosing
●Colesevelam (Welchol): 3 x 625 mg tabs twice daily or 6 tabs daily with meals
●Suspension: 3.75 g/packet once daily with largest meal
![Page 24: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/24.jpg)
Treatment Options: DA Agonists⦿Activates the DA receptor and modulates
hypothalamic control of metabolism●Does not increase plasma insulin, but rather it
decreases insulin resistance⦿Contraindicated with lactation, syncopal
migraines, or hypersensitivity to ergot derivatives or dopamine⦿Dosing
●Bromocriptine (Cycloset): 0.8mg w/in 2 hours of waking in the morning with food; titrate to 0.8 mg/week to a mean daily dose of 4.8 mg every morning
![Page 25: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/25.jpg)
Treatment Options: SGLT-2 inhibitors⦿Lowers the renal threshold and reduces
reabsorption of glucose⦿Contraindicated in CrCl <30mL/min, ESRD,
dialysis⦿Glucosuria can increase risk of UTI and
urinary frequency, risk for ketoacidosis⦿Dosing
●Canagliflozin 100 mg QD before breakfast●Dapagliflozin 5 mg QAM●Empagliflozin 10 mg QAM
![Page 26: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/26.jpg)
Treatment Options: Insulins⦿Rapid
●Novolog, Humalog, Apidra (glulisine)⦿Short
●Humulin R, Novolin R⦿Intermediate
●Novolin N, Humulin N, NPH⦿Long
●Levemir, Lantus (detemir), Tresiba (degludec), Toujeo (glargine)
![Page 27: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/27.jpg)
![Page 28: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/28.jpg)
Treatment Options: Side Effects Met GLP1
RASGLT2i
DPP-4i
AGi TZD SU/Meg
Colsvl BCR Ins Praml
Hypo mild-sev
mod-sev
Weight loss loss loss gain gain gain loss
Renal/GU
GI mod mod mod mild mod
CHF mod
Bone Fracture Risk
![Page 29: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/29.jpg)
Guidelines: AACE v ADA
⦿There is extensive overlap between the two⦿Key differences:
Biochemical Index ACE/AACE ADA
A1C ≤6.5% ≤7%
Preprandial plasma glucose
70-130 mg/dL <110 mg/dL
Postprandial plasma glucose
<180 mg/dL <140 mg/dL
![Page 30: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/30.jpg)
Guidelines
![Page 31: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/31.jpg)
![Page 32: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/32.jpg)
Carb Counting⦿Meal planning technique to manage blood
glucose levels⦿Amount of carbohydrates consumed is
dependent on the individual⦿ADA recommends starting at 45-60 grams of
carbohydrates at a meal⦿Please see handouts for easy carb counting
for patients
![Page 33: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/33.jpg)
Home Monitoring
⦿How to on testing blood sugars⦿Different monitoring systems⦿Frequency of monitoring
![Page 34: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/34.jpg)
Smart Phone Apps⦿Various ones available for free
●Glooko: for iPhone and Android○ Sync and log blood sugar levels with
doctor’s devices. FDA approved as Class II clinical device. The app is free, subscription required
●Diabetes logbook: for iPhone and Android○ Gamified logbook
●Diabetik: for iPhone○ Simple basic design that allows users to set
medication and appointments reminders based on preset information and location
![Page 35: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/35.jpg)
Think, Pair, Share: Case 1
HL is a 56 y/o obese female with a family history significant for diabetes and presents for her annual physical exam. A FPG is 170 mg/dL and she has no concerns to discuss. How should HL be managed?
A.Reassess in 1 year at her next physicalB.Obtain a f/u FPG in 1 weekC.Diagnose type 2 DM and discuss
dietary and lifestyle changes
![Page 36: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/36.jpg)
Think, Pair, Share: Case 2
AR is a 46 y/o male newly diagnosed with type 2 diabetes last month. He has a BMI of 34kg/m2 and his most recent A1C was 8.5% and has normal renal function. His FPG readings ranged from 150-180 mg/dL despite his efforts to implement dietary changes and starting to exercise more frequently.
![Page 37: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/37.jpg)
Think, Pair, Share: Case 2
Which option is best for AR?
A.Continue with diet and exercise for 1 year before trying pharmacologic treatment
B.Start metformin 500 mg twice daily titrating up to 2000 mg/day
C.Start basal insulin as his A1C indicates need for insulin therapy
D.Start glyburide 10 mg twice daily
![Page 38: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/38.jpg)
Overcoming obstacles with injectable therapyhttp://mediacenter.novomedlink.com/v/injectables-in-the-treatment-of-type-2-diabetes-a-guide-to-overcoming-patient-concerns?utm_source=nni%20media%20center&utm_medium=email&utm_content=unbranded&utm_campaign=share
![Page 39: Diabetes Presentation Pt 1 Final](https://reader036.fdocuments.in/reader036/viewer/2022062522/588a0d281a28ab132f8b5083/html5/thumbnails/39.jpg)
References⦿ https://www.aace.com/sites/all/files/diabetes-algorithm-executive-summary.pdf⦿ http://accesspharmacy.mhmedical.com.une.idm.oclc.org/content.aspx?
bookid=689&Sectionid=45310509.⦿ http://www.clinicalpharmacology-ip.com.une.idm.oclc.org/Forms/Resources/overviews.aspx⦿ http://www.nature.com/nrd/collections/type2diabetes/sponsors/index.html⦿ http://www.diabetes.org/food-and-fitness/food/what-can-i-eat/understanding-carbohydrates/carbohydrate-counting.html⦿ http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024704/⦿ http://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/basics/definition/con-20026470
⦿ ADA. I. Classification and Diagnosis. Diabetes Care 2011;34(suppl 1):S13. Table 2